# Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

> **NCT05323890** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 15 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Cell Cancer

## Interventions

- **DRUG:** Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy

## Key facts

- **NCT ID:** NCT05323890
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-20
- **Primary completion:** 2023-10-20
- **Final completion:** 2024-10-20
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05323890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05323890, "Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05323890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*